PF-Atlas › Clinical Trials › NCT05785065

Mycophenolate Mofetil in Systemic Sclerosis With Subclinical Interstitial Lung Disease

Mycophenolate Mofetil · Phase 2

Registry ID
NCT05785065
Phase
Phase 2
Status
Recruiting
Drug / intervention
Mycophenolate Mofetil
Sponsor
Centre hospitalier de l'Université de Montréal (CHUM)
Start
2024-08-29
Enrollment
35
Locations
3

About this trial

The goal of this pilot study is to assess the feasibility of a larger study on the efficacy of mycophenolate mofetil in people diagnosed with systemic sclerosis with mild lung involvement. Participants will be recruited over 12 months at 3 academic centers and assigned randomly to receive either mycophenolate mofetil or placebo, a look-alike substance that contains no active drug, for 96 weeks.

View NCT05785065 on ClinicalTrials.gov →

Explore related

All Mycophenolate Mofetil trialsAll IPF trials

Related trials

Mycophenolate mofetil — NCT01860183mycophenolate mofetil — NCT01014442Mycophenolate mofetil — NCT00883129
Medical disclaimer. This page summarizes public trial data for NCT05785065 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.